← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
BrightSpring grew FY2025 revenue 28.2%, swung to profit, and produced $394.7M of FCF, while insider sales and CEO/CFO departures add caution.
The read at a glance✓ Audited against SEC data
- Business mix — Home and community healthcareNote
- Revenue — $12.91B, +28.2%OK
- Net income — $190.7M vs lossOK
- FCF — $394.7M vs negativeOK
- Debt — $2.51B, -3.9%OK
- Insiders — 0 purchases / 9 salesWatch
- Accounting — Altman grey; Beneish clean; EQ safeNote
Business
BrightSpring is a home and community-based healthcare platform delivering pharmacy and provider services to complex patients.
Where the revenue comes from
Fiscal 2025, as BrightSpring Health Services, Inc. reports it. History and quarterly detail are in the app.
- Pharmacy Solutions$11.4B
- Provider Services$1.5B
Leadership changes
From BrightSpring Health Services, Inc.'s own filings, the day they're filed.
- Michael McMaude · Chief Executive Officer · departureeff. 2025-06-20
- Matthew D'Ambrosio · member of the board of directors · departureeff. 2024-11-12
- Walgreen Co · departureeff. 2024-11-12
Latest filings
- 8-K · Company announcement2026-07-31
- 10-Q · Quarterly report2026-07-31
- 8-K · Company announcement2026-06-12
- 8-K · Company announcement2026-06-05
- 8-K · Company announcement2026-05-21
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BrightSpring Health Services, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.